AS

ASKA Pharmaceutical Holdings CO., Ltd.

Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.

4886 | T

Overview

Corporate Details

ISIN(s):
JP3119660003
LEI:
Country:
Japan
Address:
港区芝浦二丁目5番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ASKA Pharmaceutical Holdings Co., Ltd. is the holding company for the ASKA Pharmaceutical Group, established in April 2021. The group's core business encompasses the research, development, manufacturing, and sale of pharmaceuticals. Leveraging its long-standing expertise in hormone-related technologies, the company focuses on developing innovative and original medicines, with a particular strength in therapeutic areas such as internal medicine, obstetrics and gynecology, and urology. The group's operations also extend to the animal health and hormone testing businesses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 07:10
Registration Form
確認書
Japanese 8.2 KB
2025-11-07 07:09
Interim Report
半期報告書-第5期(2025/04/01-2026/03/31)
Japanese 195.0 KB
2025-06-27 08:15
Post-Annual General Meeting Information
臨時報告書
Japanese 31.4 KB
2025-06-20 08:11
Registration Form
確認書
Japanese 8.2 KB
2025-06-20 08:10
Governance Information
内部統制報告書-第4期(2024/04/01-2025/03/31)
Japanese 28.7 KB
2025-06-20 08:08
Annual Report
有価証券報告書-第4期(2024/04/01-2025/03/31)
Japanese 1.4 MB
2025-02-07 07:41
Foreign Filer Report
臨時報告書
Japanese 21.4 KB
2024-11-08 07:04
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-08 07:02
Interim Report
半期報告書-第4期(2024/04/01-2025/03/31)
Japanese 183.3 KB
2024-06-28 07:12
Post-Annual General Meeting Information
臨時報告書
Japanese 22.0 KB
2024-06-25 06:40
Registration Form
確認書
Japanese 8.2 KB
2024-06-25 06:39
Governance Information
内部統制報告書-第3期(2023/04/01-2024/03/31)
Japanese 23.6 KB
2024-06-25 06:37
Annual Report
有価証券報告書-第3期(2023/04/01-2024/03/31)
Japanese 1.3 MB
2024-02-09 07:07
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-02-09 07:05
Quarterly Report
四半期報告書-第3期第3四半期(2023/10/01-2023/12/31)
Japanese 155.2 KB

Automate Your Workflow. Get a real-time feed of all ASKA Pharmaceutical Holdings CO., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ASKA Pharmaceutical Holdings CO., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ASKA Pharmaceutical Holdings CO., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.